Erythropoietin is a glycoprotein hormone that stimulates red blood cell production. Manufacturing companies produce synthetic variants, called erythropoiesis-stimulating agents that are used as medications for the treatment of anemia associated with conditions such as chronic kidney disease, HIV infections, or chemotherapy. Suppliers of erythropoietin market it as solutions for intravenous or subcutaneous injection. The developer and earliest manufacturer of synthetic erythropoietin (epoetin alfa) was Amgen who was first approved by the FDA to market the drug in 1989, under the trade name Epogen. Since then, various other erythropoietin products have been synthesized by pharmaceutical manufacturers, including epoetin beta, epsilon, gamma, kappa, omega, theta, zeta, as well as darbepoetin alfa. Of the latter, epoetin alfa and darbepoetin alfa account for over 80 percent of total erythropoietin market share. The expiration of Amgen’s patent has since made it possible for other manufacturers and suppliers to enter the erythropoietin market with biosimilar products. Most popular erythropoietin medications currently available on the pharmaceutical market include Aranesp (darbepoetin alfa), Epogen (epoetin alfa), Procrit (epoetin alfa), Binocrit (epoetin alfa), and Neorecormon (epoetin beta) with the first two being marketed by manufacturer and supplier Amgen, and the latter three by manufacturers and suppliers Johnson & Johnson, Novartis, and Roche respectively. Some of the adverse effects include red, heated, itchy spots on the skin (similar to nettle rash), puffiness of the lips, mouth, or throat, shortness of breath, asthma, a coughing, or abrupt difficulty breathing, and tightness or chest tightness.

Erythropoietin-stimulating agents are recombinant erythropoietin medicines (ESAs). These medications are administered via injection (shot) and act by increasing the synthesis of red blood cells. These cells are then discharged into the bloodstream from the bone marrow. Erythropoietin is a growth factor, which is a type of protein. It is produced spontaneously by the body. It works by promoting the production of red blood cells in the bone marrow, which is where blood cells are produced. Erythropoietin can also be manufactured in a laboratory for use as a therapy for anemia. EPO binds to the erythropoietin receptor on the surface of red cell progenitors, activating a JAK2 signalling cascade. The STAT5, PIK3, and Ras MAPK pathways are activated as a result. This causes the erythroid cell to differentiate, survive, and proliferate.

An online search for the wholesale price for sale of Erythropoietin for distributors will reveal a wide range of costs. It will vary from store to store depending on your visit and the country of the wholesale market. Retail prices of erythropoietin medications vary depending on the type of erythropoiesis-stimulating agent for sale, its concentration in the formulation, as well as supplier and manufacturer pricing. Costs per 6 (2000IU) prefilled syringes of fall into an approximate range of 60 EUR to 100 EUR, whereas the equivalent amount of 4000IU prefilled syringes can cost anywhere from 120 EUR to 190 EUR, and the 5000IU syringes cost from 140 EUR to 240 EUR.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Erythropoietin distributors offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for these substance manufacturers and this substance Erythropoietin suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Erythropoietin. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where Erythropoietin is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical product deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers Erythropoietin suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen Erythropoietin for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.